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Abstract
Bone involvement in human cystic echinococcosis (CE) is rare, but affects the spine in approximately 50% of cases. Despite
significant advances in diagnostic imaging techniques, surgical treatment and introduction of pharmacological therapy,
spinal echinococcosis remains associated with a high degree of morbidity, disability and mortality. We systematically
reviewed the published literature of the last five decades to update and summarize the currently existing data on treatment,
follow-up and outcome of spinal CE.
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Introduction
‘Prognosis in vertebral hydatid disease is almost hopeless as regards
complete cure. This is due to the impossibility of removing by surgical
means all diseased bone, especially if the vertebral bodies are affected, to
the multiplicity of extra-osseous cysts, to the certainty of recurrent
pressure on the cord…’ (Dew H.R., 1928) [1]
Hydatid disease or cystic echinococcosis (CE), caused by the
larval stage of the cestode Echinococcus granulosus, is a cosmopolitan
parasitic zoonosis. In the accidental human intermediate host, the
characteristic cystic lesions are mainly found in the liver (,70%)
and the lungs (,20%), but virtually any part of the body may be
affected, including the bone (,0.5–4%). The central nervous
system (which is involved in ,3% of all cases) and the vertebral
column (which is involved in $50% of the ,0.5–4% of cases
affecting the bone) [2–5] are particularly vulnerable given the
sequelae of their involvement.
‘Spinal CE’ (involvement of the spinal cord, the spine, or both
structures) is associated with a high degree of morbidity, disability,
and mortality and the prognosis has often been compared to that
of malignancies (‘le cancer blanc’ [6]), with a case fatality rate
reported to exceed 50% within 5 years after onset of symptoms
[1,3,7,8].
The treatment of choice is surgical, with removal of the intact
cyst(s) being of vital importance. Perforation of the cyst(s) during
an operation may lead to systemic dissemination and more
critically to local seeding which results in chronic recurrence.
Curative surgery remains difficult with bone involvement as
infiltration of the bone hampers unruptured and complete
resection of the cysts and high recurrence rates plague the long-
term outcome [9].
Besides surgery, the only other treatment option for spinal CE is
antiparasitic therapy with benzimidazole compounds. Since the
introduction of mebendazole (in the 1970s) and albendazole (in the
early 1980s), surgery with concomitant and subsequent benzimid-
azole administration became the widely accepted treatment
standard and in cases where surgery is not possible, these drugs
remain the only treatment option.
With recurrences presenting many years or even decades after
initial treatment of spinal CE, the assessment of treatment
outcome remains difficult. Very few retrospective and even fewer
prospective long-term follow-up studies are currently available.
We systematically reviewed the published literature of the last
five decades for case reports and case series and analyzed and
summarized the existing data on treatment, follow-up, and
outcome of spinal CE.
Methods
We performed a PubMed (MEDLINE) search of the literature
using the key words ‘spinal echinococcosis’, ‘spinal hydatidosis’,
‘spinal hydatid disease’, ‘spinal echinococcal cyst’, ‘spinal cystic
echninococcosis’ and reviewed the obtained references published
from 1965 until July 1st 2012 (figure 1; references S 1). The year
1965 was chosen, as it proved difficult to obtain articles before this
year.
All publications on clinical cases and case series of human spinal
echinococcosis published in English, French, German, Italian, and
Spanish were collected. When the original article was not
obtainable but the abstract contained data on anatomy, treatment
approach or therapeutic outcome, the publication was included in
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the analysis. In addition, the reference lists of the collected
publications were screened for supplementary (not PubMed listed)
case reports on spinal CE eligible for analysis. The collected data
included cyst location(s), anatomical structures involved (figure 2),
treatment approach(es), surgical technique(s), number of surgical
interventions, adjunct medical treatment, clinical outcome, time
frame of follow-up, and data on recurrence.
To evaluate the clinical outcome, follow-up time, and recur-
rence rates of spinal CE with regard to the involved anatomical
structures the cases were divided into intradural- extramedullar
CE, extradural-extraosseous CE and osseous CE (table 1). The
extracted data was entered into Microsoft Excel-files (Version
2002). Data on follow-up periods and recurrence periods was
summarized as medians and ranges. Nominal data was summa-
rized as frequencies and percentages.
Results
Of the 367 publications identified by electronic search, 189
publications (on 467 cases of spinal CE) were included in the
analysis (figure 1).
Data on the treatment approaches, details on the surgical
procedures, and data on the use of adjunct medical treatment are
shown in tables 2 and 3.
Discussion
Surgical treatment
Almost two centuries after Reydellet performed the first surgical
intervention on a patient with spinal CE (1819), surgery remains
the treatment of choice [7]. Depending on location and extent of
disease, the two primary tasks in surgery of spinal CE are
decompression of a compromised spinal cord and stabilisation of a
compromised spinal column. Table 2 summarizes the frequencies
Figure 1. Flow diagram of search and selection of eligible publications.
doi:10.1371/journal.pntd.0002458.g001
Author Summary
Spinal cystic echinococcosis (CE) is a rare but malignant
form of a truly neglected tropical disease. Despite modern
diagnostic imaging techniques, the advances in surgery
over the last decades and the availability of pharmacolog-
ical therapy, the clinical management of spinal CE cases
remains a challenge for the treating physician. Ten years
after the last extensive review on the topic was published
by Pamir et al. (Spinal Cord, 2002), we aim to provide
clinicians with a systematic review and comprehensive
update on spinal CE to help them deal with the often very
complex clinical management of these patients. By
systematically reviewing all published case reports and
case series of spinal CE from 1965 until now, we
summarized and analyzed the existing data on treatment,
follow-up, and outcome of the disease and discuss the
findings in light of the existing data.
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of the different surgical approaches we found in the reviewed
literature and highlights the significance of posterior decompres-
sion by laminectomy, which is performed in over 90% of all cases.
Intradural CE. Patients with cysts confined to the intradural
space typically present with acute to subacute compression of the
spinal cord and require urgent decompression. Intradural cysts are
approached posteriorly via laminectomy followed by durotomy.
The complete resection of the cysts without rupture is considered
curative and feasible in most cases, even in the presence of
adhesions to surrounding tissue [10–14]. In some cases the
excision of dura tissue together with the adherent cyst might be
necessary [12]. However, the cyst walls are very thin and fragile
and rupture might even occur at removal of free floating cysts with
only minimal arachnoidal adhesions [15]. In extensive intradural
disease, complete resection might be impossible [16]. The rapid
development of neurological symptoms leading to early diagnostic
work-up and surgery is considered to be responsible for the
favorable outcome of most patients [17]. The favorable outcome
might also be attributed to the fact that intradural CE is often
limited to a single cyst. In a series of 72 spinal CE cases the
recurrence rate (RR) of intradural CE (n= 10) was 0% and
statistically significant lower than the RR of extradural-intraspinal
(n = 17; RR=6%), paraspinal (n = 3; RR=33%), or vertebral CE
(n = 41; RR=32%) [18]. The subgroup analysis of our collected
data (3 recurrences among 20 cases [15%]) confirms the favorable
outcome of intradural CE (table 1). Of note, in two of the three
cases an explanation for recurrence was reported: rupture of cysts
at initial surgery in one case [15] and incomplete resection of the
cyst in the other [19].
Extradural-extraosseous CE. The spectrum of extradural-
extraosseous CE ranges from single epidural or paravertebral cysts
to large dumbbell formations and cases with extensive soft tissue
infiltration. As all epidural cysts and the majority of dumbbell cysts
present with spinal cord compression, decompression by laminec-
tomy is almost always part of the surgical management. To reach
paravertebral lesions, an anterior approach is usually needed. In a
case where complete excision of an intact dumbbell cyst was not
feasible, intraoperative incision and aspiration with adjacent
resection of the reachable cyst wall has been described (without
recurrence over 18 months follow-up) [20]. One case has been
published where intra- and parasacral cysts were successfully
removed by rigid endoscopy [21]. The subgroup analysis of our
collected data yields an overall recurrence rate of 27% (table 1) for
extradural-extraosseous CE, which is within the reported range of
6% (extradural-intraspinal CE) - 33% (paraspinal CE) [18]. The
two main factors determining recurrence (complete resection and
unruptured resection) might explain the higher recurrence rate of
extradural-extraosseous CE: the higher frequency of multiple cysts
and the higher rate of intraoperative cyst rupture. In a large review
on CE of the central nervous system, Altinoers and colleagues
found an intraoperative rupture rate of 16.9% for intracranial
lesions and 44.4% for intraspinal cysts, which they attributed to
Figure 2. Classification of spinal CE according to the Dew/Braithwaite & Lees classification (type 1–5) and ‘dumbbell’ formation.
doi:10.1371/journal.pntd.0002458.g002
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the discrepancy between the rather narrow space in spinal CE
with close bony boundaries and the often multiple spinal lesions
[22]. Islekel and colleagues commented that even laminectomy
almost always leads to rupture of extradural cysts [13].
Vertebral/osseous CE. In spinal CE involving bone, the
infiltrative nature of the microvesicular lesions does not allow for
unruptured resection of the cysts and therefore spillage of their
contents is inevitable [13,17,18,23]. In addition, the extent of
disease may prohibit complete resection of the affected bone and
progressive vertebral destruction may compromise stability of the
spinal column [3].
If possible, radical surgery is advocated and although often not
precluding disease progression, it has been shown to prolong
survival in selected cases [24]. The location and the extent of the
lesion(s) determine the surgical approach and the necessary
surgical procedure (table 2). After resection of affected bone, a
wide spectrum of techniques has been employed to stabilize the
vertebral column (including bone grafts [17,25–43], dorsal
stabilisation by pedicle screw systems [9,26,27,37,44–48], Har-
rington- [9,27,36,39,49–51] and Luque- [9,45,50,51] rods, verte-
bral body replacement by titanium cage implantation [44,52,53],
plating [25,35,52,54], bone cement [26,55,56]). However, in the
absence of evidence no recommendations regarding the use of a
specific technique can be given besides possibly bone grafting.
Considering that osseous grafts might be invaded by persisting or
recurrent disease, the use of acrylic cement for osteosynthesis has
been discussed [27], and in a case series of 10 patients with bone
CE (including 2 cases with spinal CE) Yildiz and colleagues
reported that the use of polymethylmethacrylate (PMMA) cement
lowered recurrence rate and prolonged the interval between
recurrences [55]. Regarding the surgical approach, two rare cases
of spinal CE affecting the craniocervical junction might be worth
mentioning for their surgical approach via an enoral route [33,43].
Among the reviewed cases with vertebral bone involvement we
found an overall recurrence rate of 48%, but the stage of disease
among the cases varied widely and data on follow-up was mostly
scarce (table 1). The available literature states a recurrence rate of
30–100% [18,24,28,38,44,57,58] and in advanced cases interven-
tions might generally be considered palliative with recurrence
inevitable [3,38]. However, remarkable cases with extensive
vertebral CE, multiple palliative operations and prolonged survival
over many years and even decades have been described [59–61].
A major limitation of the available data on recurrence of spinal
CE is the overall short follow-up period throughout the literature
(table 2) and only a few case series shed light on the long-term
prospects [3,9,24,38,55,57]. To obtain solid data on the long-term
outcome of the various forms of spinal CE, larger numbers of cases
and follow-up over many years, possibly even decades, would be
required. With follow-up periods generally not much longer or
even equal (table 1) to the observed recurrence intervals, the
current existing data probably presents an optimistic lower limit of
recurrence rates in spinal CE.
Various scolicidal agents are routinely used in surgery and
percutaneous treatment of visceral CE to sterilize the cysts at
Table 1. Number of operations, clinical outcome, follow-up, and recurrence rates.
Cyst location
No. of
cases No. of operations Clinical outcome
Follow-up median
(range)
Recurrence n (%), Dt
median (range)
Intradural- 30 1 op.: 28 (93%) complete recovery: 17 (68%) 10 months yes: 3 (15%), at
Extramedullar CE 2 op.: 2 (7%) partial recovery: 5 (20%) (2–18) 1.5, 7 & 12 months
[BL type 2] paraparesis: 3 (12%) no: 17 (85%)
no data: 5 no data: 18 no data: 10
Extradural extraossous 70 1 op.: 46 (78%) complete recovery: 23 (40%) 19 months yes: 12 (27%),
CE 2 op.: 10 (17%) nearly compl. recov.: 7 (12%) (6–108) at 22months
(epidural [BL type 3]-, 3 op.: 1 (2%) recovery unspecif.): 4 (7%) (8–48 m)
paravertebral [BL
type
6 op.: 1 (2%) partial recovery: 9 (16%) no: 32 (73%)
5]-, ‘dumbbell’-, & multiple: 1 (2%) paraparesis: 9 (16%)
posterior paraspinal paraplegia: 4 (7%)
muscle cysts) fatal postop. complication: 1 (2%)
no data: 11 no data: 16 no data: 36 no data: 22
Vertebral/osseous CE 169 1 op.: 76 (62%) complete recovery: 35 (33%) 24 months yes: 50 (48%),
[BL type 4 & cases 2 op.: 22 (18%) nearly compl. recov.: 5 (5%) (2–144) at 24 months
with involvement of 3 op.: 13 (11%) recovery (unspecif.): 5 (5%) (3–156)
posterior vertebral 4 op.: 1 (1%) partial recovery: 32 (30%) no: 53 (52%)
elements] 5 op.: 6 (5%) monoparesis: 1 (1%)
6 op.: 2 (1%) paraparesis: 8 (7%)
7 op.: 1 (1%) paraplegia: 17 (16%)
8 op.: 1 (1%) tetraplegia: 1 (1%)
death: 3 (3%)
no data: 47 no data: 62 no data: 113 no data: 71
BL: Braithwaite & Lees classification.
doi:10.1371/journal.pntd.0002458.t001
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intervention, with 95% ethanol and 20% hypertonic saline being
the most frequently used solutions [62]. In vitro studies have
demonstrated a dose- and time- dependent effect: the higher the
concentration and the longer the exposure time, the greater and
faster the scolicidal effect [63,64]. As rupture of cysts at surgery of
spinal CE is a central problem, most surgeons advocate the use of
scolicidal agents to irrigate the operative field, although the
efficacy of this measure remains unproven and potentially
deleterious effects on neural tissue have to be considered
[7,18,65]. Various agents have been deployed: 3%–7.2% hyper-
tonic saline, povidone iodine, ethacrine lactate (rivanol), hydrogen
peroxide, silver nitrate, cetrimide, formalin [9,18,41,45,65–71]. In
a case series of 66 spinal CE cases no significant difference in
recurrence rate was observed between the intraoperative use of
3% saline-, 10% formaldehyde- or 0.5% silver nitrate/povidone
iodine-solution [18]. However, in light of the above mentioned in
vitro studies, the use of hypertonic saline with concentrations lower
than 20% appears to be questionable. The use of 20% hypertonic
saline in spinal CE has been reported and appears to be safe even
for intradural irrigation [13,26,58,72]. Ten per cent formaline
solution is considered safe in cranial CE, but possibly dangerous in
spinal CE: a fatal case related to toxic myelitis following dural tear
has been published [13]. A case of coma and hemolysis following
epidural irrigation with cetrimide has been reported [73]. Even
though scolicidal agents are not active against intact microscopic
daughter cysts (which demand chemotherapy), they are effective
Table 2. Treatment approach in 437 spinal CE cases.
Treatment (n =437) No. of cases Surgical approach N (%) Notes
Surgery *
surgical approach 284 posterior only 217 186 laminectomy only
specified (76.4) 4 hemilaminectomy only
3 costotransversectomy only
24 laminectomy+posterior stabilization/fusion (incl.
pedicle screw-systems, Harrington- & Luque-rods,
bone grafting)
anterior { & posterior 46 (16.2) laminectomy+various ant. & post. procedures
(incl. curettage, vertebrectomy, bone grafting,
vertebral body replacement by titanium cage
implantation, pedicle screw-systems, Harrington-
& Luque-rods, plating)
anterior { only 21 (7.4) various procedures (incl. curettage,
vertebrectomy, bone grafting, vertebral body
replacement by titanium cage implantation,
plating)
surgical approach not specified 143
Medical treatment with albendazole
only
8 Belhassen-Garcia 2011 [109], Sudo 2010 [82], Kotil
2010 [87], Tug˘cu 2008 [110], Rkain 2007 [111], El
Kohen 2003 [83], Kuremu 2002 [84], Poggianti
1997 [112]
PAIR+albendazole 2 Ozdemir 2011 [56], Spektor 1997 [76]
*6 adjunct medical treatment with benzimidazoles (see table 3).
{anterior: transthoracic, transabdominal, retroperitoneal, and transoral.
doi:10.1371/journal.pntd.0002458.t002
Table 3. Surgery and adjunct benzimidazole treatment in 420 spinal CE cases.
Surgery & adjunct benzimidazole treatment* No. of cases Notes
Adjunct medical treatment mentioned:
Surgery+benzimidazole treatment 151 median time of treatment [n = 106]:
6 months (3 weeks - indefinite) dosages:
albendazole: 10–15 mg/kg/d
mebendazole: 40–60 mg/kg/d
Surgery+benzimidazole+praziquantel 12 Lam 1997 (1 case) [59]; Keller 1997 (1 case) [35]; El-On 2003 (1 case) [48]; Hamdan 2012 (9
cases) [38]
Surgery without adjunct medical treatment 2 Pandey 1997 (unruptured resection of a single cyst from the sacral spinal canal) [89];
Hamdan 2000 (total excision of a thoracic dumbbell hydatid cyst) [88]
No adjunct medical treatment mentioned 174
Published before the availability of benzimidazoles 81
*albendazole or mebendazole.
doi:10.1371/journal.pntd.0002458.t003
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against spilled protoscolices from ruptured cysts and therefore
considered a valuable adjunct to radical surgery and chemother-
apy [4].
Besides leading to disease recurrence, the spillage of cyst content
during surgery may provoke various hypersensitivity reactions,
ranging from pruritus, urticaria, rash, edema, bronchospasm, and
gastrointestinal symptoms to hypotension and fatal anaphylactic
shock [74]. Although frequently being quoted, data on the
incidence of anaphylactic reactions during surgery of CE
(including spinal CE) remains scarce. Among the reviewed cases
we found only two reports on severe anaphylactic reactions during
surgery: a case of cardiovascular collapse and bronchospasm [9]
and a case where resection of lesions adhering to the abdominal
aorta led to arterial dissemination of daughter cysts and fatal
anaphylaxis [38]. Even though anaphylactic reactions are rarely
reported, it has to be considered, that non-severe anaphylactic
reactions may remain undetected under general anaesthesia [75].
Some authors have advocated the use of glucocorticosteroids to
prevent anaphylactic shock during surgery [26,76]. It has been
observed that the risk for anaphylactic shock appears to rise with
the number of surgical operations and therefore some authors
have used intradermally injected hydatid echinococcal antigen for
‘desensitization’ [61,67]. The same approach has also been tried as
‘biological therapy’ [77,78]. However, data remained disputable
and both approaches were abandoned when medical treatment
with mebendazole became available.
Medical treatment
Therapy with benzimidazole derivatives has shown to be
effective in visceral CE [79] although a recent systematic review
concluded that treatment response depends on cyst stage and size,
and that efficacy of medical treatment may have been overstated
in the past [80].
Data on the efficacy of benzimidazoles in osseous CE is scarce
and the contribution of these drugs to cure or even prevent
recurrence in vertebral CE is frequently debated [38,57]. Todorov
and colleagues investigated factors influencing the efficacy of
benzimidazoles and found, besides larger cyst size and the
presence of daughter cysts, especially bone involvement to be
unfavorable [81].
However, various publications have reported favorable results
attributed to medical treatment: several authors have used
albendazole in patients with inoperable spinal CE (table 3) and
some reported favorable results even in cases with extensive
disease [59,82–84]. In a study of 40 patients with inoperable
vertebral hydatitosis El-Mufti and colleagues reported a cure rate
of 53% with albendazole treatment at a minimal follow-up time of
two years [85]. From long-term follow-up of surgical spinal CE
cases Islekel and colleagues concluded that adjunct pharmaco-
therapy appears to retard recurrence [13]. The successful medical
treatment of a residual cyst (post surgery) with a one year course of
albendazole has been reported (follow-up time at publication: one
year) [86]. Kotil and colleagues reported successful albendazole
treatment of a solitary extradural lumbar cyst in a patient
presenting with mild neurological symptoms and concluded that
medical treatment might be suitable for patients with solitary
lesions in the absence of indications for immediate surgery (no
neurological deficit or spinal instability) [87].
Among the reviewed cases, adjunct pharmacotherapy was used
in 98.8% of all cases (table 3). In the only 2 cases where
deliberately no adjunct medical treatment was given, the authors
reported complete resection without spillage of the cysts [88,89].
In the absence of pharmacokinetic data on benzimidazoles in
bone or spinal soft tissue, most authors use the dosages
recommended by the World Health Organisation (WHO) for
visceral CE (mebendazole 40–50 mg/kg/day; albendazole 10–
15 mg/kg/day [90]), with albendazole being preferred over
mebendazole due to the better pharmacokinetic properties and
superior efficacy [91,92]. Considering the high to inevitable risk of
cyst rupture, perioperative treatment with albendazole should be
initiated $4 hours before surgery to achieve scolicidal blood levels
[93]. The addition of praziquantel to albendazole is sometimes
advocated due to the protoscolicidal effect of praziquantel.
However, data on the efficacy of this approach is currently
missing [94]. The optimal duration of medical treatment has not
been determined, neither for visceral CE nor for osseous CE or the
various forms of spinal CE. Among the reviewed cases most
authors preferred 6 months of treatment (table 3). In some cases
with extensive disease even indefinite medical treatment has been
reported [53].
Due to the observed high inter-individual variablity of maximal
albendazole sulphoxide levels and taking into account drug-
interactions, it has been proposed to increase albendazole
bioavailability (and blood levels of the active metabolite albenda-
zole sulphoxide) by coadministration of cimetidine. However, data
on interactions of cimetidine with intestinal absorption and hepatic
metabolization of albendazole remains conflicting and the issue
controversial [95,96].
Medical treatment with albendazole might not be able to cure
or prevent recurrence of spinal CE, but it remains the only
treatment option for inoperable patients and the use of drug
therapy in conjunction to surgery is generally considered useful to
decrease the risk of recurrence, delay recurrence and prevent
seeding from intraoperative cyst spillage.
Besides benzimidazoles, few other medical treatment options
have been tried in osseous CE and their role remains to be defined:
Among the reviewed cases, we found four publications where
albendazole plus praziquantel combination therapy was used
(table 3) [35,38,48,59]. As these were either case reports or case
series without a control group, the efficacy of this combination
remains to be defined. Like cimetidine, praziquantel enhances the
bioavailability of albendazole [97,98].
Three publications on five cases of osseous CE and adjunct
nitazoxanide treatment have been published [99–101]. As these
were case reports, the efficacy of adjunct nitazoxanide treatment
remains to be defined.
Percutaneous treatment
We found two cases where CT-guided percutaneous treatment
using the PAIR approach (Puncture of the cyst, Aspiration of the
cyst fluid, Injection of a scolicidal agent, and Re-aspiration of the
cyst content) has been reported (table 2).
Spektor and colleagues reported successful percutaneous
treatment in a patient with a cervical vertebral hydatid cyst (C2-
3) extending into the spinal canal and causing severe spinal cord
compression. The intervention led to rapid decompression and
clinical improvement. No adverse events were observed and
follow-up over one year showed favorable imaging results with
complete resolution of clinical symptoms. The authors concluded
that percutaneous treatment might be particularly beneficial in
cases with extensive disease where radical removal is impossible
[76].
Ozdemir and colleagues reported the use of PAIR in a patient
who had undergone complex surgery for thoracic spinal CE before
(partial corpectomy, posterior fusion with transpedicular screws,
bone cement) and presented with severe paraparesis due to
recurrent disease. Two vertebral cysts extending into the spinal
canal and causing severe spinal cord compression were successfully
Spinal Echinococcosis - Systematic Review - Part 2
PLOS Neglected Tropical Diseases | www.plosntds.org 6 September 2013 | Volume 7 | Issue 9 | e2458
treated by bilateral transpedicular interventions. No adverse events
were observed and follow-up over six months showed favorable
imaging results with complete resolution of clinical symptoms. The
authors concluded that percutaneous treatment should be
considered in cases where prior surgical interventions aggravate
re-operation [56].
Radiotherapy
In 1965 Fitzpatrick reported the use of radiotherapy in a case
with extensive spinal CE and noted that no apparent benefit of this
treatment accrued [61]. Sporadically, the use of radiotherapy as
an adjunct to surgery and medical treatment has been reported in
cerebral and osseous CE, but data regarding the efficacy of this
approach is pending [22,102,103]. Experimental studies evaluated
the use of radiotherapy in rodent models and depicted a dose
depending effect on scolex viability in osseus CE [104] and
inhibition of E. multilocularis larval growth [105–107]. Recently a
case report describing the successful use of radiotherapy in a
patient with sternal E. multilocularis infection with failed multiple
surgical procedures and medical treatment has been published
[108].
Conclusion
Despite significant advances in diagnostic imaging techniques
and surgical treatment, spinal echinococcosis remains associated
with a high degree of morbidity, disability and mortality.
Surgery is the treatment of choice with decompression of a
compromised spinal cord and stabilization of a compromised spinal
column being the two primary tasks.
The long-term outcome depends on complete resection of all
parasitic lesions, which is frequently hampered by the infiltrative
nature of the disease.
Recurrence rates of spinal CE are high, especially in cases with
vertebral bone involvement.
The currently existing data on follow-up of spinal CE cases is
largely insufficient to judge the long-term outcome of surgery.
Besides surgery, the intraoperative use of scolicidals and the
pre-, peri-, and postoperative use of albendazole is currently
considered the treatment standard of spinal CE.
The role of combination drug therapy, percutaneous treatment
and radiotherapy in spinal CE remains to be defined.
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